Latest news with #HarmonyBiosciences
Yahoo
23-07-2025
- Business
- Yahoo
Harmony Biosciences Advances Pipeline While Navigating Analyst Caution
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is one of the . Mixed analysts' sentiments for the stock, following the presentation of preclinical data for BP1.15205. A close-up of a pharmaceutical drug bottle, showcasing the potential of the company's innovative therapies. Headquartered in New Jersey, Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is a commercial-stage pharmaceutical company engaged in the process of developing therapies for rare neurological and sleep disorders. The company's lead product, WAKIX® (pitolisant), treats excessive daytime sleepiness in narcolepsy, with additional pipeline treatments for Prader‑Willi Syndrome and myotonic dystrophy. On June 11, 2025, the company announced new preclinical data for BP1.15205. Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) claimed that this unique chemical scaffold is a potential best-in-class orexin-2 agonist. The company's data indicates BP1.15205 has notable wake-promoting and cataplexy-suppressing effects in narcolepsy type-1 mouse models. With plans to initiate human trials in the later part of 2025, the company strengthens its foothold in the sleep-wake disorder treatment market, with BP1.15205. Following this announcement, Mizuho Securities and H.C. Wainwright maintained their Buy rating on the stock. Deutsche Bank also keeps a Buy rating for the stock while raising the price target from $54 to $55. Goldman Sachs, however, sticks to their Hold rating on the company. Amid these mixed ratings, Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) maintains its position as a low-risk stock with high growth potential by offering a beta of 0.84 with an EPS growth of 25.93% for the next five years. While we acknowledge the potential of HRMY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Metal Stocks with Insider Buying in 2025 and 10 Energy Stocks with Insider Buying in 2025 Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
22-07-2025
- Business
- Globe and Mail
Harmony Biosciences to Report Second Quarter 2025 Financial Results on August 5, 2025
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report second quarter 2025 financial results on Tuesday, August 5, 2025, before the open of the U.S. financial markets. Harmony will host a conference call and webcast on August 5, 2025, at 8:30 a.m. ET to discuss the results. To participate in the call, please dial 833-316-2483 (domestic) or 785-838-9284 (international), and reference passcode HRMYQ225. It is recommended that you dial in at least 10 minutes prior to the call. The live and replay webcast of the call will be available on the investor page of our website at About Harmony Biosciences Harmony Biosciences is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases who have unmet medical needs. Driven by novel science, visionary thinking, and a commitment to those who feel overlooked, Harmony Biosciences is nurturing a future full of therapeutic possibilities that may enable patients with rare neurological diseases to truly thrive. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, Pa., we believe that when empathy and innovation meet, a better future can begin; a vision evident in the therapeutic innovations we advance, the culture we cultivate, and the community programs we foster. For more information, please visit
Yahoo
22-07-2025
- Business
- Yahoo
Harmony Biosciences to Report Second Quarter 2025 Financial Results on August 5, 2025
PLYMOUTH MEETING, Pa., July 22, 2025--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report second quarter 2025 financial results on Tuesday, August 5, 2025, before the open of the U.S. financial markets. Harmony will host a conference call and webcast on August 5, 2025, at 8:30 a.m. ET to discuss the results. To participate in the call, please dial 833-316-2483 (domestic) or 785-838-9284 (international), and reference passcode HRMYQ225. It is recommended that you dial in at least 10 minutes prior to the call. The live and replay webcast of the call will be available on the investor page of our website at About Harmony Biosciences Harmony Biosciences is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases who have unmet medical needs. Driven by novel science, visionary thinking, and a commitment to those who feel overlooked, Harmony Biosciences is nurturing a future full of therapeutic possibilities that may enable patients with rare neurological diseases to truly thrive. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, Pa., we believe that when empathy and innovation meet, a better future can begin; a vision evident in the therapeutic innovations we advance, the culture we cultivate, and the community programs we foster. For more information, please visit View source version on Contacts Harmony Biosciences Investor Contact: Brennan Doyle484-539-9700bdoyle@ Harmony Biosciences Media Contact: Cate McCanless202-641-6086cmccanless@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
22-07-2025
- Business
- Business Wire
Harmony Biosciences to Report Second Quarter 2025 Financial Results on August 5, 2025
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report second quarter 2025 financial results on Tuesday, August 5, 2025, before the open of the U.S. financial markets. Harmony will host a conference call and webcast on August 5, 2025, at 8:30 a.m. ET to discuss the results. To participate in the call, please dial 833-316-2483 (domestic) or 785-838-9284 (international), and reference passcode HRMYQ225. It is recommended that you dial in at least 10 minutes prior to the call. The live and replay webcast of the call will be available on the investor page of our website at About Harmony Biosciences Harmony Biosciences is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases who have unmet medical needs. Driven by novel science, visionary thinking, and a commitment to those who feel overlooked, Harmony Biosciences is nurturing a future full of therapeutic possibilities that may enable patients with rare neurological diseases to truly thrive. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, Pa., we believe that when empathy and innovation meet, a better future can begin; a vision evident in the therapeutic innovations we advance, the culture we cultivate, and the community programs we foster. For more information, please visit
Yahoo
17-07-2025
- Business
- Yahoo
Why Harmony Biosciences (HRMY) is Poised to Beat Earnings Estimates Again
Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Harmony Biosciences Holdings, Inc. (HRMY), which belongs to the Zacks Medical - Biomedical and Genetics industry, could be a great candidate to consider. This company has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarters was 23.53%. For the most recent quarter, Harmony Biosciences was expected to post earnings of $0.78 per share, but it reported $0.59 per share instead, representing a surprise of 32.20%. For the previous quarter, the consensus estimate was $0.74 per share, while it actually produced $0.85 per share, a surprise of 14.86%. Price and EPS Surprise With this earnings history in mind, recent estimates have been moving higher for Harmony Biosciences. In fact, the Zacks Earnings ESP (Expected Surprise Prediction) for the company is positive, which is a great sign of an earnings beat, especially when you combine this metric with its nice Zacks Rank. Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank #3 (Hold) or better produce a positive surprise nearly 70% of the time. In other words, if you have 10 stocks with this combination, the number of stocks that beat the consensus estimate could be as high as seven. The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier. Harmony Biosciences currently has an Earnings ESP of +19.75%, which suggests that analysts have recently become bullish on the company's earnings prospects. This positive Earnings ESP when combined with the stock's Zacks Rank #2 (Buy) indicates that another beat is possibly around the corner. Investors should note, however, that a negative Earnings ESP reading is not indicative of an earnings miss, but a negative value does reduce the predictive power of this metric. Many companies end up beating the consensus EPS estimate, though this is not the only reason why their shares gain. Additionally, some stocks may remain stable even if they end up missing the consensus estimate. Because of this, it's really important to check a company's Earnings ESP ahead of its quarterly release to increase the odds of success. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Harmony Biosciences Holdings, Inc. (HRMY) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
